Verici Dx Regulatory News (VRCI)

Verici Dx plc

("Verici Dx" or the "Company")

Completion of CAP accreditation audit

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists ("CAP"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.

The inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now. We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians."